Equities

IXICO PLC

IXICO PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)6.88
  • Today's Change0.00 / 0.00%
  • Shares traded185.02k
  • 1 Year change-63.82%
  • Beta0.7179
Data delayed at least 20 minutes, as of Jun 14 2024 16:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

  • Revenue in GBP (TTM)6.00m
  • Net income in GBP-1.87m
  • Incorporated1995
  • Employees89.00
  • Location
    IXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
  • Phone+44 203 763 7499
  • Fax+44 207 209 2473
  • Websitehttps://ixico.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ovoca Bio PLC0.00-1.97m736.12k5.00--0.1725-----0.0241-0.02410.000.05230.00----0.00-27.00-17.82-32.86-19.39--------4.68-48.640.00-------6.96------
Nuformix PLC0.00-436.95k1.60m2.00--0.346-----0.0006-0.00060.000.00560.00-------9.50---9.95--------------0.00--------------
Hellenic Dynamics PLC-100.00bn-100.00bn1.92m25.00--2.24----------0.006----------------------------0.3029--------------
ReNeuron Group Plc249.00k-5.07m1.93m34.00--0.7966--7.75-0.0888-0.08880.00440.04240.0246--0.64427,323.53-50.10-43.12-101.09-58.50-----2,037.35-714.73----0.1247--31.5165.2644.18---1.31--
N4 Pharma PLC1.95k-1.28m1.97m5.00--1.19--1,012.26-0.0053-0.00530.000010.00420.0011--0.009390.00-74.20-57.05-79.41-61.13-----65,475.90-309,312.80----0.00-----51.52-24.05------
CRISM' Therapeutics Corp0.00-1.89m2.38m4.00--0.1953-----0.2167-0.87450.000.37350.00----0.00-14.26-8.67-14.89-9.02-----------3.510.00------8.21------
Fusion Antibodies PLC1.58m-2.84m3.29m50.00--1.41--2.08-0.0861-0.08610.04360.02450.52293.151.8831,580.00-93.94-31.29-130.56-37.72-7.4142.58-179.67-48.252.32--0.0313---39.551.52-116.33---23.83--
IXICO PLC6.00m-1.87m3.32m89.00--0.3312--0.554-0.0386-0.03860.12410.20760.4725--3.5467,415.73-14.694.35-16.585.3346.9062.09-31.106.61----0.03120.00-22.894.32-214.15--92.12--
ValiRx Plc9.60k-2.04m3.44m8.00--0.8266--358.44-0.0201-0.02010.000090.03150.0027--0.0682---59.88-50.57-58.27-54.7785.00---22,164.48-103,908.502.32-520.030.0075------13.89---1.13--
TheraCryf PLC396.00k-3.14m4.17m9.00--1.14--10.52-0.0114-0.01140.00140.00850.0858--0.976644,000.00-67.93-42.50-81.69-46.66-----792.17-1,482.46----0.00---10.41--22.41------
Cizzle Biotechnology Holdings PLC0.00-1.72m5.75m67.00--3.50-----0.0048-0.00480.000.00410.00-------76.69-144.15-82.81-167.75-----------0.8050.00-------88.27------
BSF Enterprise PLC67.24k-1.71m5.94m4.00--1.49--88.37-0.0166-0.01660.00070.03870.01281.790.042516,810.00-32.47---34.78---44.74---2,542.56--6.17-218.850.0287-------61.40------
Data as of Jun 14 2024. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX

Institutional shareholders

50.85%Per cent of shares held by top holders
HolderShares% Held
BGF Investment Management Ltd.as of 04 Dec 20238.92m18.46%
Octopus Investments Ltd.as of 04 Dec 20236.41m13.25%
Canaccord Genuity Wealth Ltd.as of 30 Mar 20214.68m9.69%
Hargreaves Lansdown Asset Management Ltd.as of 01 Feb 20241.76m3.63%
City Asset Management Plcas of 29 Jan 20241.43m2.95%
ICBC Standard Bank Plcas of 01 Feb 2024610.00k1.26%
Pilling & Co. Stockbrokers Ltd.as of 01 Feb 2024267.00k0.55%
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024223.00k0.46%
Acadian Asset Management LLCas of 01 Feb 2024151.00k0.31%
BG Fund Management Luxembourg SAas of 01 Feb 2024137.00k0.28%
More ▼
Data from 31 Mar 2024 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.